• Explore /
  • Poster
  • / Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).

Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).

Abstract Poster

Authors

Nicholas Zdenkowski

Nicholas Zdenkowski

Australia and New Zealand Breast Cancer Trials Group, Newcastle, Australia

Nicholas Zdenkowski , Michael Green , Frances M. Boyle , George Kannourakis , Peter Grantley Gill , Evan Bayliss , Christobel Saunders , Stephen Della-Fiorentina , Neill Kling , Ian Campbell , Val Gebski , Anne-Sophie Veillard , Lucy Claire Davies , Rochelle Thornton , Akiko Fong , Linda Louise Reaby , John F. Forbes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

01260700013749

Citation

J Clin Oncol 33, 2015 (suppl; abstr 514)

DOI

10.1200/jco.2015.33.15_suppl.514

Abstract #

514

Poster Bd #

2

Abstract Disclosures

Similar Posters

First Author: Hao Liao

First Author: Michael Untch

First Author: Gerrit-Jan Liefers

First Author: Francesco Perrone